Company Background
Hyphens Pharma International Limited (Hyphens) is a Singapore-based specialty pharmaceutical and consumer healthcare group with a footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.
In terms of valuation, the stock trades at around 10.2x price to earnings and 1.5x price to book. The stock currently offers a decent dividend yield of 2.8%.
Milestones
Date |
Event |
1998 |
Started with investment in Pan-Malayan Pharmaceuticals. |
2001 |
Acquisition of Hyphens Pharma. |
2004 |
Started operation in Malaysia. |
2007 |
Started operation in the Philippines. |
2008 |
Completed the acquisition of Pan-Malayan Pharmaceuticals from founders. |
2010 |
Hyphens received the prestigious E50 Award. |
2011 |
Started operation in Indonesia. Launch of Ceradan, the first proprietary brand owned by Hyphens Pharma. |
2013 |
Transformation of Pan-Malayan Pharmaceuticals as a wholesaler to “The Medical Hypermart. Pan-Malayan Pharmaceuticals received the prestigious E50 Award. |
2016 |
Acquisition of Ocean Health. Hyphens Pharma and Singapore’s Agency for Science, Technology and Research (A*STAR) inked MoU to be Strategic Dialogue Partners in the Field of Dermatology. |
2017 |
Filed for a patent in the UK. |
2018 |
Listed on Catalist, SGX-ST. Moved into Corporate Headquarters and Integrated Facility. |
2019 |
Official Opening of Hyphens Pharma International Limited’s Corporate Headquarters and Integrated Facility
|
Revenue
Revenue for Hyphens grew 54% from S$78mn in FY15 to S$121mn in FY18. Hyphens’ revenue is broken down into three segments.
Hyphens engages in the business of selling and marketing specialty pharmaceutical products. Hyphens maintains long-term relationships with many of its brand principals and, through exclusive distributorship or licensing and supply agreements with the relevant brand principals, Hyphens markets and sells a range of specialty pharmaceutical products in the relevant ASEAN countries. Revenue from this segment accounted for 57% of FY18’s total revenue (Figure 1).
To sell these specialty pharmaceuticals, Hyphens has to secure the rights from brand principals which are mainly from Europe and the United States. Some of the principals that Hyphens represents are:
Business model of specialty pharma
The therapeutic focuses which Hyphens targets its specialty pharmaceuticals:
Dermatology, paediatrics and neonatology, allergy, otorhinolaryngology (ear, nose and throat), orthopaedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry and family medicine.
The major specialty product brands for Hyphens include contrast media products, Stérimar® nasal sprays, Bausch+Lomb eye drops, Vivomixx ™, Fenosup® Lidose® and Piascledine®.
2. Proprietary brands
Hyphens develops, markets and sells its own proprietary range of dermatological products under their Ceradan® and TDF® brands, and health supplement products under their Ocean Health® brand. Hyphens own the formulation, trademark and right to appoint contract manufacturers to produce the products, and sell it anywhere in the world. Revenue from this segment accounted for 11% of total revenue in FY18 (Figure 1).
Business model of Proprietary brands
3. Medical hypermart and digital platform
Hyphens engages in the wholesale of pharmaceuticals and medical supplies in Singapore through Pan-Malayan, which is a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies. Revenue from this segment accounted for 32% of FY18’s total revenue (Figure 1).
In addition, the online platform was also upgraded with educational materials, some of which are recognised under the Singapore Medical Association’s Continuing Medical Education (“CME”) programme which allows doctors to earn CME points as part of their practicing requirements. This expands the appeal of the online Medical Hypermart to beyond inventory restocking.
Business model of Medical Hypermart and Digital Platform
Margins
Gross profit margin improved from 32.8% in FY2017 to 33.7% in FY2018 and this was largely attributable to the increased contribution from the specialty pharma principals and proprietary brands segments, which have comparatively higher margins than the medical hypermart and digital segment.
Dividends
Hyphens does not have a fixed dividend policy. However, the Board intends to recommend and distribute dividends of at least 30% of its net profits attributable to our Shareholders for each of 2018 and 2019, as they wish to reward Shareholders for participating in the Group’s growth.
Cost
Large cost components are marketing and distribution costs, making up 64% of total OPEX in FY18 (Figure 8). Hyphens’ ability to scale its business is contingent on its ability to grow its marketing and distribution network to enhance its presence in existing jurisdictions and expand its product reach in new geographical markets. Hence a large proportion of spending is allocated to increase the quality and size of Hyphens’ marketing and distribution network, which will affect its distribution capacity, and, accordingly, sales volumes.
Cash-flow
A strength of Hyphens’ business model is the minimal capital expenditure required in the business. PPE only make up only 5% of FY18’s total assets. With minimal capex required, FCF yield stood at 7.0% in FY18. This allows Hyphens to sustain its dividend of S$0.0055 per share in FY19, translating into a modest 2.8% yield. High FCF also helps the group to build its war chest for future acquisitions.
Balance Sheet
Assets: Of the S$75mn total assets, almost 32% is cash (S$24mn), 35% is trade and other receivables (S$26mn) and 14% is inventories (S$10mn).
Liabilities: Hyphens’ total liabilities stand at S$34mn, with trade and other payables accounting for 83%.
Competitors
Some of Hyphens’ competitors include:
Customers
Hyphens’ customers for each segment:
Industry
Strong economic growth in ASEAN countries with increased health expenditure. In tandem with the economic growth in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, these countries have seen an increase in total health expenditure.
Increased life expectancy with an aging population. Life expectancy in ASEAN countries has increased significantly. This, coupled with decreasing fertility rates, have resulted in an aging population profile across ASEAN countries. An aging population is expected to result in increased healthcare expenditure and continued economic development of ASEAN countries is expected to drive this spending with rising affluence. This may, in turn, increase demand for Hyphens’ products.
Increase in Prevalence of Atopic Dermatitis. Studies have shown a statistical correlation between urban environments and atopic dermatitis and accordingly, there is a substantial market for products for the management of atopic dermatitis, such as our Ceradan® products, with the rise in urbanisation of ASEAN countries.
Investment Highlights
Valuations
In terms of valuation, the stock trades at around 10.2x price to earnings and 1.5x price to book. The stock currently offers a decent dividend yield of 2.8%.
Min Ying covers the Banking and Finance sectors. She has experience in external audit and corporate tax roles.
She graduated with a Bachelor of Accountancy with a major in Finance from SMU.